JORNAY PM vs LISDEXAMFETAMINE DIMESYLATE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. JORNAY PM and LISDEXAMFETAMINE DIMESYLATE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	JORNAY PM	LISDEXAMFETAMINE DIMESYLATE
Rating	New	70/100
Pharmacy pays	~$18.94 /30	—
Type	RX	RX
Active ingredient	METHYLPHENIDATE HYDROCHLORIDE	LISDEXAMFETAMINE DIMESYLATE
Manufacturer	Ironshore Pharms	Ascent Pharms Inc
Dosage forms	Capsule	Capsule, Tablet, chewable
Drug class	Central Nervous System Stimulant	Central Nervous System Stimulant
Boxed warning	Boxed warning	Boxed warning
Half-life	about 2.7 hours	less than 1 hour (parent drug)
Treats	Attention Deficit Disorder with Hyperactivity, Depressive Disorder, Narcolepsy	Attention Deficit Disorder with Hyperactivity, Binge Drinking

jornay pm lisdexamfetamine dimesylate

Rating

New

70/100

Pharmacy pays

~$18.94 /30

—

Type

Active ingredient

METHYLPHENIDATE HYDROCHLORIDE

LISDEXAMFETAMINE DIMESYLATE

Manufacturer

Ironshore Pharms

Ascent Pharms Inc

Dosage forms

Capsule

Capsule, Tablet, chewable

Drug class

Central Nervous System Stimulant

Boxed warning

Half-life

about 2.7 hours

less than 1 hour (parent drug)

Treats

Attention Deficit Disorder with Hyperactivity, Depressive Disorder, Narcolepsy

Attention Deficit Disorder with Hyperactivity, Binge Drinking

Frequently asked questions

What is the difference between Jornay Pm and Lisdexamfetamine Dimesylate?

Jornay Pm contains Methylphenidate Hydrochloride, while Lisdexamfetamine Dimesylate contains Lisdexamfetamine Dimesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.